SummaryJust because we can’t meet at sPCMA doesn’t mean we can’t discuss what’s next for Medicare Part D.
Our experts engaged in a conversation about the outlook for the Part D program and issues to watch during the 2021 bid/contracting cycle and beyond. Our panelists explored the potential implications of a preferred specialty tier on 2021 and 2022 formularies, the future of Part D benefit redesign, and some key impacts across different types of Part D plans.
Our panelists also answered questions from the audience.
produces measurable results. Let's work together.